Материалов:
1 005 012

Репозиториев:
30

Авторов:
596 024

По вашему запросу найдено документов: 36391

Страница 1 из 3640

Clinical observation experience of a pediatric patient with primary progressive multiple sclerosis in the moscow office for the treatment of children and adolescents with multiple sclerosis
Bykova O.V., Klimov Y.A., Tikhonov S.V., Lalabekova M.V., Boyko E.A., Batysheva T.T., Boyko A.N.
Objective. To demonstrate the experience of a personalized approach to the treatment of pediatric
Survey of diagnostic and treatment practices for multiple sclerosis in Russian Federation in comparison to European data
Boykо, A., Fernández, O., Alifirova, V., Babicheva, N., Bakhtiyarova, K., Volkov, A., Glavinskaya, N., Goncharova, Z., Greshnova, I., Smagina, I., Lashch, N., Inzhinova, A.
to start with the second line of disease-modifying therapy (DMT), a lower percentage would choose dimethyl
COVID-19 immunopathology and the central nervous system: Implication for multiple sclerosis and other autoimmune diseases with associated demyelination
Boziki M.K.
, such as an Extended Interval Dose (EID) of Disease-Modifying Treatment (DMT) administration, in order to minimize
The Role of D-Serine and D-Aspartate in the Pathogenesis and Therapy of Treatment-Resistant Schizophrenia
Nasyrova, Regina F., Khasanova, Aiperi K., Altynbekov, Kuanysh S., Asadullin, Azat R., Markina, Ekaterina A., Gayduk, Arseny J., Shipulin, German A., Petrova, Marina M., Shnayder, Natalia A.
the search for new therapeutic strategies for a disease-modifying therapy for treatment-resistant Sch (TRS
Nutritional modulation of the intestinal microbiota: future opportunities for the prevention and treatment of neuroimmune and neuroinflammatory disease
Lombardi V., De Meirleir K., Subramanian K., Nourani S., Dagda R., Delaney S., Palotás A.
microbiome and neuroimmune and neuroinflammatory diseases. In most cases, it is unknown if these associations
Basic principles for the management of neurological patients during the COVID-19 pandemic
Kopishinskaya S.V.
disease modifying drugs, the treatment of stroke patients are discussed. The data from the international
Potential uses of upadacitinib in rheumatoid arthritis and other inflammatory rheumatic diseases [ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ УПАДАЦИТИНИБА ПРИ РЕВМАТОИДНОМ АРТРИТЕ И ДРУГИХ ИММУНОВОСПАЛИТЕЛЬНЫХ РЕВМАТИЧЕСКИХ ЗАБОЛЕВАНИЯХ]
Nasonov E.L.
with the development of a wide range of genetically engineered biological disease-modifying anti-rheumatic drugs (b
Treatment of the amyotrophic lateral sclerosis using of genetically modified umbilical cord blood mononuclear cells in the preclinical studies
Rizvanov A., Guseva D., Salafutdinov I., Bashirov F., Kiiasov A., Islamov R.
of transplantation of gene modified UCBC for treating neurodegenerative diseases. In the review we discuss
Development of Celecoxib Granules for Manufacturing of Prolonged Release Celecoxib Capsules and Tablets
Alkhodri A., Suslina S.N.
of the latest generation for the treatment of inflammatory diseases of the musculoskeletal system
Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience
Zagrebneva A.I., Simonova E.N., Mezenova T.V., Burmistrova N.B., Gavrikova Yu.A., Dolgov V.V., Morozova E.O., Kodzeva Zh.M., Sapogina K.S.
in combination with synthetic disease-modifying antirheumatic drugs (sDMARDs) and/or glucocorticoids (GCs) were

Страница 1 из 3640

Фасеты

Новости проекта

Новости

Партнеры

КФУ
ТГУ
Elpub
СФУ
Webpublishers

Индексация

BASE
WorldCat
OpenAIRE
EDS
core